The article by Matsui et al.
1 comes 9 years after our own study dealing with the same topic, that is, the value of CD34 enumeration in bone marrow (BM) to separate hypoplastic myelodysplastic syndrome (h-MDS) and aplastic anemia (AA). 2 The results that the authors report in their study are remarkably similar to ours. Differences in the microwave retrieval process may explain the slightly different percental values obtained by immunohistochemistry. Similar to the authors, we also found a statistically significant difference between the two groups (h-MDS vs AA).
The paper by Matsui et al. 1 is, however, highly inaccurate in the way it quotes our previous study. The authors seem to imply that we did not observe significant differences between the two groups and they stress the 'overlapping' results obtained by several groups and by us (see authors' reference 10). This is totally false. Our results speak for themselves. Our conclusions were the following: 'Bone marrow specimens of h-MDS cases showed statistically higher values of proliferating cell nuclear antigen (PCNA) and CD34 than did those of the AA cases: mean values (7s.d.) of CD34-positive cells in h-MDS, 0.94%71.1; AA, 0.04%70.1 (P ¼ 0.0002); PCNA-positive cells in h-MDS, 43.59%713.3; AA, 14.80%76.4 (Po0.0001)'. Our study confirms that AA is characterized by low expression of PCNA in bone marrow and reduced CD34 frequency compared with h-MDS and supports the concept of an early deficiency of stem cells in the former disorder. The results also illustrate how immunostaining permits a simple distinction of these conditions in routinely processed BM biopsy specimens'. The use of PCNA in this diagnostic context was previously reported by Kitagawa et al. 3 Additionally, the comments in regard to our database, which are found in the discussion section (last page of the discussion, sentence beginning with 'Although Orazi et aly') are also quite inappropriate. Our cases were diagnosed in accordance with the French-American-British guidelines and were not 'misclassified'. Marrow karyotype was normal in only 28% of our cases of MDS. Contrary to what the authors seem to imply, a large proportion of patients with h-MDS do have indeed normal cytogenetics and an indolent clinical course. The separation of AA and h-MDS is problematic only in these cases and not in the group of MDS with an increased number of blasts (i.e. refractory anemia with excess of blasts). The utility of a correct separation between the two conditions lies in the need for a different conditioning regimen when bone marrow transplant is considered, particularly in younger patients with AA, and not necessarily in its prognostic value.
It is truly discouraging to note how some of our younger colleagues are eager to 'reinvent the wheel'. The intent of our study 1, 2 was not to displace previous reports (including the one authored by Dr Orazi), 3 but rather to provide further evidence that quantification of CD34 þ cells can serve as a useful discriminator between aplastic anemia (AA) and hypoplastic myelodysplastic syndrome (hMDS). Dr Orazi is, in fact, misquoting our paper when he states that we imply that his group did not observe significant differences between the two groups. We acknowledge throughout our paper that the study of Orazi et al.
2 demonstrated a significant difference in the mean percentage of CD34 þ cells from patients classified as having either hMDS or AA. Further, our statement that there is overlap in the range of values given for the hMDS group is quite accurate, with a lower limit (0.1%) in these patients that is equal to the upper value given for those in the AA group. A potential confounding factor in their analysis may have come from reliance on the FAB guidelines to accurately diagnose patients, as those patients with normal cytogenetics and erythroid dysplasia as the sole morphologic abnormality may have in fact have had AA.
Despite the paper published 9 years ago by Dr Orazi and coworkers, enumeration of CD34 in the marrow has not become a standard test for what remains a clinical dilemma, distinguishing AA from hMDS. This is in part, we believe, because CD34 numbers, although statistically different between the disease groups, showed considerable overlap in several studies. Rather than attempting to 'reinvent the wheel,' we believe that our results build upon past studies by providing clinical outcomes that improve the ability to classify patients with either disease state. When doing this, we find no overlap in marrow CD34 numbers between AA and hMDS, and thus believe quantifying marrow CD34 numbers should be further tested as a standard approach for separating the two disorders. Furthermore, these findings also suggest that patients with normal cytogenetics and low CD34 þ percentages are at a low risk of disease progression and may be managed in a conservative manner in the absence of life-threatening cytopenias. I did appreciate the reply letter from Dr Matsui et al., 1 which I believe clarifies most of the issues I had raised in reference to their recent paper.
2 However, their reply, which refers to 'a potential confounding factor in their (our) analysis 3 may have come from reliance on the FAB guidelines to accurately diagnose patients', is still somewhat misleading. Although the presence of a cytogenetic abnormality is useful in confirming a suspected diagnosis of myelodysplastic syndrome (MDS), its present is not mandated by either FAB or WHO 2001 guidelines. The diagnostic criteria for MDS in both classifications largely overlap. Therefore, the assumption that we might have 'misclassified' cases because of the use of FAB (the only system available in 1996) is incorrect.
I completely agree with Dr Matsui et al. 1 that the enumeration of bone marrow CD34 positive cells should be further tested, possibly in a randomized prospective way, in order to conclusively confirm its validity for separating the two disorders. The fact that the 'CD34 approach' has not become standard of practice up to now, I suspect, it is also due to the usual interlaboratory variability which plagues immunohistochemistry laboratories in general. As this is not likely to change in the near future, the best approach to this difficult differential diagnosis remains, in my judgment, a comprehensive one inclusive of morphology, immunohistology, flow cytometry and cytogenetics. Marrow cytogenetics still maintains its major prognostic role in this group of hypoplastic marrow disorders.
